Dolomite Microfluidics and Mologic collaborate to scale-up manufacture of nanoparticles for COVID-19 diagnostic tests


As the COVID-19 pandemic progresses in countries around the globe, there is an urgent need for rapid and reliable point-of-need detection testing. Dolomite Microfluidics and Mologic are working together to accelerate development and launch these tests.


UK-based company, Mologic is a leading developer of rapid response diagnostic tests for diseases such as malaria and Ebola virus disease. Clients include the Bill & Melinda Gates Foundation where Mologic is leveraging core technology through its Centre for Advanced Rapid Diagnostics (CARD) to develop the next-generation of ultra-sensitive point-of-care diagnostics which are easy to use and inexpensive to manufacture – critical to the success of many global health programmes. Most recently, Mologic has received UK Government funding to develop and manufacture a high sensitivity test for COVID-19 that generates results within minutes – rather than hours or days – without the need for a scientific laboratory or specialist equipment. 


The technology behind these tests involves the use of precisely manufactured nanoparticles. Dolomite specialises in equipment which allows development and scale-up of precision nanoparticles. This is achieved by using microfluidic technology to retain advanced control of production conditions. Dolomite is working with Mologic to combine ground-breaking diagnostic technology with continuous flow microfluidic manufacturing processes to accelerate the validation and wide-release of Mologic’s COVID-19 diagnostic test.